Abstracts tagged "safety and tuberculosis"

Abstract Number: 2628 • 2016 ACR/ARHP Annual Meeting
Retention of Use and Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: A Patient Record Assessment in a Compassionate Use Programme in South Africa, a Tuberculosis Endemic Country
I Louw¹, M Ally², DC Janse van Rensburg², E Van Duuren³, D Nel³, H Miller-Janson⁴, M de Necker⁴, JC de Beer⁴ and H Duvenhage⁵, ¹Panorama Medical Centre, Cape Town, South Africa, ²University of Pretoria, Pretoria, South Africa, ³Jacaranda Hospital, Pretoria, South Africa, ⁴HEXOR (PTY) Ltd, Pretoria, South Africa, ⁵Bristol-Myers Squibb, Johannesburg, South Africa
Background/Purpose: South Africa is a tuberculosis (TB) endemic country having one of the highest TB infection rates in the world with close to 1000 cases…
Abstract Number: 1222 • 2015 ACR/ARHP Annual Meeting
The Risk of Tuberculosis (TB) in Rheumatoid Arthritis Patients Treated with TNF Inhibitors and the Safety of Resuming Biologic Dmards for Patients Who Developed TB after Anti-TNF Treatment
Soo-Kyung Cho¹, Dam Kim¹, Hye-Jin Jeong², Il Woong Sohn², Soyoung Won³, Minkyung Han³, Jiyoung Lee³, Eun Jin Jang⁴, Sang-Cheol Bae¹ and Yoon-Kyoung Sung¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Information Statistics, Andong National University, Andong-si, South Korea
Background/Purpose: The association between TNF inhibitor (TNFI) treatment and the development of tuberculosis (TB) has been confirmed through several observational studies. Current guidelines strongly recommend…
Abstract Number: 1817 • 2012 ACR/ARHP Annual Meeting
The Role of Repeating Tuberculin Skin Tests During Biologic Therapy
Joseph R. Lutt¹ and Kevin L. Winthrop², ¹Colorado Center for Arthritis & Osteoporosis, Boulder, CO, ²Dept of Infectious Disease, Oregon Health & Science University, Portland, OR
The Role of Repeating Tuberculin Skin Tests during Biologic TherapyBackground/Purpose: Prior to starting biologic therapy, it is recommended that all patients be screened for tuberculosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].